These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

173 related items for PubMed ID: 8101126

  • 1. Alprazolam and exposure alone and combined in panic disorder with agoraphobia. A controlled study in London and Toronto.
    Marks IM, Swinson RP, Başoğlu M, Kuch K, Noshirvani H, O'Sullivan G, Lelliott PT, Kirby M, McNamee G, Sengun S.
    Br J Psychiatry; 1993 Jun; 162():776-87. PubMed ID: 8101126
    [Abstract] [Full Text] [Related]

  • 2. Alprazolam and exposure for panic disorder with agoraphobia. Attribution of improvement to medication predicts subsequent relapse.
    Başoğlu M, Marks IM, Kiliç C, Brewin CR, Swinson RP.
    Br J Psychiatry; 1994 May; 164(5):652-9. PubMed ID: 7921716
    [Abstract] [Full Text] [Related]

  • 3. Relationship of panic, anticipatory anxiety, agoraphobia and global improvement in panic disorder with agoraphobia treated with alprazolam and exposure.
    Başoğlu M, Marks IM, Kiliç C, Swinson RP, Noshirvani H, Kuch K, O'Sullivan G.
    Br J Psychiatry; 1994 May; 164(5):647-52. PubMed ID: 7921715
    [Abstract] [Full Text] [Related]

  • 4. Comment on the London/Toronto Study of Alprazolam and Exposure in Panic Disorder with Agoraphobia.
    Spiegel DA, Roth M, Weissman M, Lavori P, Gorman J, Rush J, Ballenger J.
    Br J Psychiatry; 1993 Jun; 162():788-9; discussion 790-4. PubMed ID: 8101127
    [No Abstract] [Full Text] [Related]

  • 5. Safety and side-effects of alprazolam. Controlled study in agoraphobia with panic disorder.
    O'Sullivan GH, Noshirvani H, Başoğlu M, Marks IM, Swinson R, Kuch K, Kirby M.
    Br J Psychiatry; 1994 Jul; 165(1):79-86. PubMed ID: 7802851
    [Abstract] [Full Text] [Related]

  • 6. Memory functions, alprazolam and exposure therapy: a controlled longitudinal study of agoraphobia with panic disorder.
    Curran HV, Bond A, O'Sullivan G, Bruce M, Marks I, Lelliot P, Shine P, Lader M.
    Psychol Med; 1994 Nov; 24(4):969-76. PubMed ID: 7892364
    [Abstract] [Full Text] [Related]

  • 7. Pre-treatment predictors of treatment outcome in panic disorder and agoraphobia treated with alprazolam and exposure.
    Başoğlu M, Marks IM, Swinson RP, Noshirvani H, O'Sullivan G, Kuch K.
    J Affect Disord; 1994 Feb; 30(2):123-32. PubMed ID: 7911132
    [Abstract] [Full Text] [Related]

  • 8. Panic disorder with agoraphobia.
    Klein DF.
    Br J Psychiatry; 1993 Dec; 163():835-7. PubMed ID: 7905776
    [No Abstract] [Full Text] [Related]

  • 9. Sequence of improvement in agoraphobia with panic attacks.
    Rifkin A, Pecknold JC, Swinson RP, Ballenger JC, Burrows GD, Noyes R, Dupont RL, Lesser I.
    J Psychiatr Res; 1990 Dec; 24(1):1-8. PubMed ID: 2195163
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Discontinuation reactions to alprazolam in panic disorder.
    Pecknold JC.
    J Psychiatr Res; 1993 Dec; 27 Suppl 1():155-70. PubMed ID: 8145176
    [Abstract] [Full Text] [Related]

  • 12. Behavioural and combined therapy in panic states.
    Pecknold JC.
    Prog Neuropsychopharmacol Biol Psychiatry; 1987 Dec; 11(2-3):97-104. PubMed ID: 2888162
    [Abstract] [Full Text] [Related]

  • 13. Agoraphobia and panic disorder: 3.5 years after alprazolam and/or exposure treatment.
    Kiliç C, Noshirvani H, Başoğlu M, Marks I.
    Psychother Psychosom; 1997 Dec; 66(4):175-8. PubMed ID: 9259039
    [Abstract] [Full Text] [Related]

  • 14. Alprazolam in panic disorder and agoraphobia: results from a multicenter trial. II. Patient acceptance, side effects, and safety.
    Noyes R, DuPont RL, Pecknold JC, Rifkin A, Rubin RT, Swinson RP, Ballenger JC, Burrows GD.
    Arch Gen Psychiatry; 1988 May; 45(5):423-8. PubMed ID: 3358644
    [Abstract] [Full Text] [Related]

  • 15. Clinical and medication outcome after short-term alprazolam and behavioral group treatment in panic disorder. 2.5 year naturalistic follow-up study.
    Nagy LM, Krystal JH, Woods SW, Charney DS.
    Arch Gen Psychiatry; 1989 Nov; 46(11):993-9. PubMed ID: 2818144
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. A fixed-dose study of alprazolam 2 mg, alprazolam 6 mg, and placebo in panic disorder.
    Lydiard RB, Lesser IM, Ballenger JC, Rubin RT, Laraia M, DuPont R.
    J Clin Psychopharmacol; 1992 Apr; 12(2):96-103. PubMed ID: 1573046
    [Abstract] [Full Text] [Related]

  • 19. Treatment of panic disorder with agoraphobia: randomized placebo-controlled trial of four psychosocial treatments combined with imipramine or placebo.
    Marchand A, Coutu MF, Dupuis G, Fleet R, Borgeat F, Todorov C, Mainguy N.
    Cogn Behav Ther; 2008 Apr; 37(3):146-59. PubMed ID: 18608313
    [Abstract] [Full Text] [Related]

  • 20. Fading of therapeutic effects of alprazolam in agoraphobia. Case reports.
    Fava GA.
    Prog Neuropsychopharmacol Biol Psychiatry; 1988 Apr; 12(1):109-12. PubMed ID: 3363164
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.